DBP International: Dossier for Inofer acquired
In 2019 a clinical study was conducted in a collaboration between Double Bond Pharmaceutical AB (“Double Bond”) and Skellefteå Lasarett. The study showed that iron succinate significantly improves iron uptake, iron saturation and iron storage in patients with heart failure and iron deficiency. Today, December 7 2020 Double Bond and Laboratorie X.O (France) signed an agreement for the acquisition and rights of Inofer©´s (iron succinate) registration dossier for the Nordic market.
"We are pleased with the positive clinical results of ferrous succinate´s use. We strongly believe in the great market potential of the drug” – comments Igor Lokot, CEO at Double Bond – “The purchase of the dossier is the next important step for the development and marketing of the product on the Nordic market".
More about clinical study: https://mb.cision.com/Main/12720/2972792/1151388.pdf
More about Drugsson AB: www.drugsson.com
____________________________________________________________________
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Follow us on LinkedIn and Twitter!
______________________________________________________________________________
Information about Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired the rights of Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for marketing in EU and globally and has the working name SI-053 in the DBP pipeline.